Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP351412.RADpGojIQOhf4i-bLdHkhzWPqCKQE1-G55nMSk-E9ZZGY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP351412.RADpGojIQOhf4i-bLdHkhzWPqCKQE1-G55nMSk-E9ZZGY130_assertion type Assertion NP351412.RADpGojIQOhf4i-bLdHkhzWPqCKQE1-G55nMSk-E9ZZGY130_head.
- NP351412.RADpGojIQOhf4i-bLdHkhzWPqCKQE1-G55nMSk-E9ZZGY130_assertion description "[Of 8 patients with erbB-2 amplification, 5 had a complete response (CR) or minimal residual disease (MRD), 3 had a partial response (PR), and none had stable (StD) or progressive disease (PD) at the time of mastectomy, versus 3 CR or MRD, 16 PR, and 8 StD or PD for patients without amplification (P = 0.008).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP351412.RADpGojIQOhf4i-bLdHkhzWPqCKQE1-G55nMSk-E9ZZGY130_provenance.
- NP351412.RADpGojIQOhf4i-bLdHkhzWPqCKQE1-G55nMSk-E9ZZGY130_assertion evidence source_evidence_literature NP351412.RADpGojIQOhf4i-bLdHkhzWPqCKQE1-G55nMSk-E9ZZGY130_provenance.
- NP351412.RADpGojIQOhf4i-bLdHkhzWPqCKQE1-G55nMSk-E9ZZGY130_assertion SIO_000772 11948114 NP351412.RADpGojIQOhf4i-bLdHkhzWPqCKQE1-G55nMSk-E9ZZGY130_provenance.
- NP351412.RADpGojIQOhf4i-bLdHkhzWPqCKQE1-G55nMSk-E9ZZGY130_assertion wasDerivedFrom befree-2016 NP351412.RADpGojIQOhf4i-bLdHkhzWPqCKQE1-G55nMSk-E9ZZGY130_provenance.
- NP351412.RADpGojIQOhf4i-bLdHkhzWPqCKQE1-G55nMSk-E9ZZGY130_assertion wasGeneratedBy ECO_0000203 NP351412.RADpGojIQOhf4i-bLdHkhzWPqCKQE1-G55nMSk-E9ZZGY130_provenance.